Markets:

Overview

News

Currencies

International

Treasuries

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (NQ:KNSA)

43.65 -0.27 (-0.61%)

Streaming Delayed Price Updated: 9:30 AM EST, Feb 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

< Previous 1 2 3 4 Next >

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines High Growth Momentum with Strong Technical Setup ↗

January 29, 2026

Via Chartmill

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Fits the High-Growth Momentum and Trend Template Strategy ↗

December 13, 2025

KNSA stock meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including surging EPS and revenue.

Via Chartmill

Kiniksa (KNSA) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Kiniksa (KNSA) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Combines Technical Strength and Fundamental Growth Momentum ↗

November 20, 2025

KNSA stock shows strong technical momentum per the Minervini Trend Template and impressive fundamental growth with 421% EPS growth.

Via Chartmill

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

What to Expect from Kiniksa Pharmaceuticals's Earnings ↗

October 27, 2025

Via Benzinga

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

Earnings Preview: Kiniksa Pharmaceuticals ↗

July 28, 2025

Via Benzinga

Earnings Scheduled For April 29, 2025 ↗

April 29, 2025

Via Benzinga

5 Analysts Have This To Say About Kiniksa Pharmaceuticals ↗

October 17, 2025

Via Benzinga

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Identified by High Growth Momentum and Minervini Trend Screen ↗

October 08, 2025

Kiniksa Pharma (KNSA) is a high-growth momentum stock in a strong technical uptrend, with surging earnings and sales supporting its price advance.

Via Chartmill

What Analysts Are Saying About Kiniksa Pharmaceuticals Stock ↗

September 29, 2025

4 analysts have expressed a variety of opinions on Kiniksa Pharmaceuticals (NASDAQ: KNSA) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Via Benzinga

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shows High-Growth Momentum and Strong Technical Setup ↗

September 24, 2025

Kiniksa Pharmaceuticals (KNSA) shows explosive EPS growth of 483% and strong technicals, trading near 52-week highs in a consolidation pattern that suggests a potential breakout.

Via Chartmill

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Emerges as an Affordable Growth Opportunity ↗

September 22, 2025

Kiniksa Pharmaceuticals (KNSA) offers strong growth potential at a reasonable valuation. With 125% EPS growth, no debt, and a forward P/E of 21.47, it's a compelling affordable growth stock.

Via Chartmill

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top Affordable Growth Candidate ↗

September 01, 2025

Kiniksa Pharma (KNSA) is a strong affordable growth stock with impressive revenue & EPS growth, a reasonable valuation, and a solid debt-free balance sheet.

Via Chartmill

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Exhibits High Growth Momentum and Technical Breakout Potential ↗

August 25, 2025

Kiniksa Pharma (KNSA) shows strong earnings growth and a bullish technical setup, making it a high-growth momentum stock to watch for a potential breakout.

Via Chartmill

KINIKSA PHARMACEUTICALS INTE (NASDAQ:KNSA): A Strong Growth Stock with a Positive Technical Breakout ↗

August 22, 2025

Kiniksa Pharma (KNSA) is a strong growth stock with 125% EPS growth, a debt-free balance sheet, and a bullish technical breakout pattern.

Via Chartmill

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) – An Affordable Growth Stock with Strong Fundamentals and Fair Valuation ↗

August 08, 2025

Affordable Growth investing targets stocks like Kiniksa Pharmaceuticals (KNSA), balancing strong revenue/earnings growth with fair valuations and financial health. KNSA shows high growth (8/10), solid...

Via Chartmill

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Aligns with Minervini’s Trend Model as a Strong Momentum Pick ↗

August 05, 2025

Kiniksa Pharmaceuticals (KNSA) aligns with Minervini’s Trend Model, showing strong technicals, rapid earnings growth, and upward momentum—ideal for growth investors.

Via Chartmill

Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket ↗

August 04, 2025

Via Benzinga

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter? ↗

August 04, 2025

The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria.

Via Investor's Business Daily

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 25, 2025

Via Benzinga

Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth ↗

July 02, 2025

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

May 05, 2025

Via Benzinga

Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? ↗

May 04, 2025

Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them?

Via Benzinga

Topics Artificial Intelligence

These stocks are gapping in today's session ↗

April 29, 2025

Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday ↗

April 29, 2025

Via Benzinga

Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook ↗

April 28, 2025

Via Benzinga

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now ↗

March 14, 2025

Via The Motley Fool

Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst ↗

March 06, 2025

Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.